Science

Pipeline

Highly prioritized clinical programs

Dovitinib logo
Dovitinib is a Pan-Tyrosine Kinase Inhibitor (TKI)
Phase
1
2
3

Dovitinib

no text
  • Exclusively in-licensed (globally) from Novartis
  • Efficacy in Phase 3 trial in Renal Cell Carcinoma (RCC) and in Phase 2 trials in 4 other cancers
  • Mechanism-of-Action:  Small molecule, targeted inhibitor of  FGFR, VEGFR, and other RTKs
  • GMP & FDA  approved Drug manufacturing is completed- clinical drug supply available.
  • Dovitinib DRP® is validated in 5 different cancers: RCC, GIST, liver, metastatic breast, and endometrial 
  • Clear Regulatory Approval Pathway- Pre-NDA meeting (U.S. FDA) for “non-inferiority” vs. Sorafenib in RCC targeted for 2020. Subsequent NDA filing for RCC with Dovitinib DRP®
  • Large market potential with high unmet market need: Global RCC therapeutics market projected to grow to $6.3B by 2022.  Annual sales of Nexavar® = $715 M in 2018.   
logo
Stenoparib (formerly 2X-121) has a novel dual-inhibitory action against both PARP 1/2 and Tankyrase 1/2
Phase (cancer)
1
2
3

Stenoparib

no text
Phase (Coronavirus)
1
2
3

Stenoparib

no text
  • Exclusively in-licensed (globally) from Eisai.
  • Efficacy in Phase 1 trial, including ovarian and pancreatic cancer
  • Multi Target Mechanism-of-Action:  First in class small molecule targeted inhibitor of DNA damage repair enzymes (PARP)1 and telomerase maintenance enzymes (Tankyrase).
  • Multi-targeted inhibitor: PARP 1/2 and Tankyrase 1/2 
  • Limited drug resistance: Lack of transport by P-glycoprotein potentially overcomes resistance to PARP inhibitors
  • GMP & FDA approved drug manufacturing is completed – clinical drug supply available.
  • Stenoparib DRP® is validated.
  • Clear Clinical Development Pathway – Phase 2 trials ongoing in ovarian cancer (Dana-Farber Cancer Institute, Boston, MA USA). Completion of Phase 2 trials targeted for 2021.
  • Broad Combination Therapy – as mono-agent or combination with DNA damaging agents with immuno-oncology drugs
  • Possibly a therapy against Coronavirus, based on properties of a comparable PARP inhibitor.
 
Ixempra® (ixabepilone) is a cell-cycle specific antimicrotubule agent. It attaches to a section of the microtubule and thereby acts on the microtubule structure and function of the cell. Oncology Venture's Ixempra study has not yet commenced.
Phase
1
2
Approved

Ixempra (US), owned by R-Pharm

no text
Phase
1
2
3

Ixempra (EU)

no text
  • Exclusively in-licensed (Europe) from R-PHARM U.S.
  • Approved in the U.S. for mBC patients.
  • Mechanism-of-Action: Small molecule targeted inhibitor of microtubules (cell cytoskeleton components crucial to cell division and stability)
  • GMP & FDA  approved Drug manufacturing is completed – clinical drug supply available.
  • IXEMPRA® DRP® is validated in metastatic breast cancer.
  • Clear Clinical Development Path – Phase 2 trial front-line, neoadjuvant therapy in newly diagnosed breast cancer.
  • Enrollment of Phase 2 trials targeted for 2020.
  • Large market potential with high unmet market need: Global breast cancer therapeutics market projected to grow to $25Billion by 2024.  Market potential for IXEMPRA® as front-line neoadjuvant therapy in newly-diagnosed breast cancer.

Other clinical programs

Oncology Venture has a wide pipeline of anti-cancer treatments. Dovitinib, Stenoparib and Ixempra® are high-priority clinical programs.

LiPlaCis, 2X-111, and Irofulven are other assets in the company's pipeline.

LiPlaCis®

Enables a more targeted delivery at the tumor site of cisplatin
Phase
1
2
3/pivotal

LiPlaCis

no text

On 29 June 2020 LiPlaCis® was out-licensed to Smerud Medical Research International AS.

2X-111

Glutathione-enhanced, PEGylated Liposomal Doxorubicin
Phase
1
2
3

2X-111

no text

On 29 June 2020 LiPlaCis® was out-licensed to Smerud Medical Research International AS.

Irofulven

This drug candidate is a synthetic drug candidate based on a naturally occurring substance that exploits a deficiency in the DNA repair mechanism of cancer cells in a manner similar to a PARP inhibitor.
Phase
1
2
3

Irofulven

no text

 

Irofulven is a unified product consisting of a synthetic drug and an accompanying DRP®, Oncology Venture’s unique companion diagnostic.

The irofulven drug alkylates DNA and protein macromolecules, forms adducts, and arrests cells in the S-phase of the cell cycle. This agent requires NADPH-dependent metabolism by alkenal/one oxidoreductase for activity.

Want to keep updated on news from Oncology Venture? Sign up to our press releases here: